抗EGFR治疗在头颈部鳞癌中的研究进展

doi:10.11904/j.issn.1002-3070.2023.03.014

实用肿瘤学杂志 ›› 2023, Vol. 37 ›› Issue (3): 276-280.doi: 10.11904/j.issn.1002-3070.2023.03.014

抗EGFR治疗在头颈部鳞癌中的研究进展

伦立鑫, 钟振滨, 赵新宇, 吴筹综述, 郝春成审校

哈尔滨医科大学附属肿瘤医院头颈放疗科(哈尔滨 150081)

收稿日期:2022-11-10 修回日期:2023-04-27 出版日期:2023-06-28 发布日期:2023-08-07
通讯作者: 郝春成,E-mail:haochuncheng1980@163.com
作者简介:伦立鑫,男,(1997-),硕士研究生,从事肿瘤临床放化疗的研究。

Research progress of anti-EGFR therapy in head and neck squamous cell carcinoma

LUN Lixin, ZHONG Zhenbin, ZHAO Xinyu, WU Chou, HAO Chuncheng

Department of Head and Neck Radiotherapy,Harbin Medical University Cancer Hospital,Harbin 150081,China

Received:2022-11-10 Revised:2023-04-27 Online:2023-06-28 Published:2023-08-07

摘要/Abstract

摘要： 表皮生长因子受体(Epidermal growth factor receptor,EGFR)在头颈部鳞状细胞癌(Head and neck squamous cell carcinoma,HNSCC)的发生发展中发挥重要作用。EGFR作为一种生物标志物,参与多种信号通路,且在HNSCC中高表达。目前,一系列抗EGFR靶向治疗药物相继用于HNSCC的临床研究及治疗,包括西妥昔单抗、尼妥珠单抗和阿法替尼等。本文就HNSCC抗EGFR的治疗现状和研究进展作一综述,以期为药物选择及预后等提供参考。

关键词: 头颈部鳞状细胞癌, 表皮生长因子受体, 靶向治疗, 安全性

Abstract: Epidermal growth factor receptor(EGFR)plays an important role in the occurrence and development of head and neck squamous cell carcinoma(HNSCC).EGFR,as a biomarker,participates in multiple signaling pathways and is highly expressed in HNSCC.At present,a series of anti-EGFR targeted therapy drugs have been used in clinical research and treatment of HNSCC,including cetuximab,nituzumab,afatinib,etc.This article provides a review of the current treatment status and research progress of HNSCC anti-EGFR,in order to provide a reference for drug selection and prognosis.

Key words: Squamous cell carcinoma of the head and neck, Epidermal growth factor receptor, Targeted therapy, Security

中图分类号:

R733.1

伦立鑫, 钟振滨, 赵新宇, 吴筹, 郝春成. 抗EGFR治疗在头颈部鳞癌中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(3): 276-280.

LUN Lixin, ZHONG Zhenbin, ZHAO Xinyu, WU Chou, HAO Chuncheng. Research progress of anti-EGFR therapy in head and neck squamous cell carcinoma[J]. Journal of Practical Oncology, 2023, 37(3): 276-280.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2023.03.014

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2023/V37/I3/276

参考文献

1 Gao L,Zhang A,Yang F,et al.Immunotherapeutic strategies for head and neck squamous cell carcinoma(HNSCC):current perspectives and future prospects[J].Vaccines,2022,10(8):1272.
2 Verma J,Dhingra V,Srivastava S,et al.Evaluation of epidermal growth factor receptor expression by a new scoring system in head-and-neck squamous cell carcinoma and its association with various pathological prognostic factors[J].J Oral Maxillofac Pathol,2018,22(1):11-17.
3 Cramer JD,Burtness B,Le QT,et al.The changing therapeutic landscape of head and neck cancer[J].Nat Rev Clin Oncol,2019,16(11):669-683.
4 Xu X,Li R,Zhang L,et al.Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma[J].Diagn Pathol,2021,16(1):110.
5 Nair S,Bonner JA,Bredel M.EGFR mutations in head and neck squamous cell carcinoma[J].Int J Mol Sci,2022,23(7):3818.
6 Patel B,Saba NF.Current aspects and future considerations of EGFR inhibition in locally advanced and recurrent metastatic squamous cell carcinoma of the head and neck[J].Cancers,2021,13(14):3545.
7 Yang Z,Liao J,Schumaker L,et al.Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma[J].Oral Oncol,2022,131:105939.
8 Peng X,Zhou Y,Tao Y,et al.Nasopharyngeal carcinoma:the role of the EGFR in epstein-barr virus infection[J].Pathogens,2021,10(9):1113.
9 Caldieri G,Malabarba MG,Di FP,et al.EGFR trafficking in physiology and cancer[J].Prog Mol Subcell Biol,2018,57:235-272.
10 Byeon HK,Ku M,Yang J.Beyond EGFR inhibition:multilateral combat strategies to stop the progression of head and neck cancer[J].Exp Mol Med,2019,51(1):1-14.
11 Ang KK,Berkey BA,Tu X,et al.Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma[J].Cancer Res,2002,62(24):7350-7356.
12 Fasano M,Della Corte CM,Viscardi G,et al.Head and neck cancer:the role of anti-EGFR agents in the era of immunotherapy[J].Ther Adv Med Oncol,2021,13:1758835920949418.
13 Zaryouh H,De PI,Baysal H,et al.Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma[J].Med Res Rev,2022,42(1):112-155.
14 Kumar P,Mangla B,Javed S,et al.Gefitinib:An updated review of its role in the cancer management,its nanotechnological interventions,recent patents and clinical trials[J].Recent Pat Anticancer Drug Discov,2023,18(4):448-469.
15 Patil VM,Noronha V,Joshi A,et al.A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer[J].Cancer,2019,125(18):3184-3197.
16 Martins RG,Parvathaneni U,Bauman JE,et al.Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck:a randomized phase II trial[J].J Clin Oncol,2013,31(11):1415-1421.
17 Burtness B,Haddad R,Dinis J,et al.Afatinib vs placebo as adjuvant therapy after chemoradiotherapy in squamous cell carcinoma of the head and neck:a randomized clinical trial[J].JAMA Oncol,2019,5(8):1170-1180.
18 Tang X,He J,Li B,et al.Efficacy and safety of gefitinib in patients with advanced head and neck squamous cell carcinoma:a meta-analysis of randomized controlled trials[J].J Oncol,2019,5:6273438.
19 Bonner JA,Harari PM,Giralt J,et al.Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck[J].N Engl J Med,2006,354(6):567-578.
20 She L,Tian K,Han J,et al.Pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy to treat recurrent or metastatic head and neck squamous cell carcinoma:an updated KEYNOTE-048 based cost-effectiveness analysis[J].Oral Oncol,2022,129:105871.
21 Seiwert TY,Fayette J,Cupissol D,et al.A randomized,phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck[J].Ann Oncol,2014,25(9):1813-1820.
22 Hecht M,Hahn D,Wolber P,et al.A prospective real-world multi-center study to evaluate progression-free and overall survival of radiotherapy with cetuximab and platinum-based chemotherapy with cetuximab in locally recurrent head and neck cancer[J].Cancers,2021,13(14):3413.
23 Huang TL,Chuang HC,Tsai MH,et al.Stereotactic body radiotherapy plus cetuximab for previously irradiated un-resectable head and neck cancer[J].Biomed J,2021,45(5):838-846.
24 Sano D,Fujisawa T,Tokuhisa M,et al.Real-world treatment outcomes of the EXTREME regimen as first-line therapy for recurrent/metastatic squamous cell carcinoma of the head and neck:a multi-center retrospective cohort study in Japan[J].Anticancer Res,2019,39(12):6819-6827.
25 Surmeli ZG,Ozveren A,Arslan C,et al.Biweekly cetuximab in combination with platinum and 5-fluorouracil in metastatic head and neck carcinoma[J].Indian J Cancer,2019,56(1):4-8.
26 Buchbinder EI,Desai A.CTLA-4 and PD-1 pathways similarities,differences,and implications of their inhibition[J].Am J Clin Oncol,2016,39(1):98-106.
27 Seiwert TY,Burtness B,Mehra R,et al.Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck(KEYNOTE-012):an open-label,multicenter,phase 1b trial[J].Lancet Oncol,2016,17(7):956-965.
28 Ferris RL,Blumenschein G,Fayette J,et al.Nivolumab for recurrent squamous-cell carcinoma of the head and neck[J].New Engl J Med,2016,375(19):1856-1867.
29 Sacco AG,Chen R,Worden FP,et al.Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma:an open-label,multi-arm,non-randomised,multicentre,phase 2 trial[J].Lancet Oncol,2021,22(6):883-892.

[1]	陈琪, 何明旭, 贾科良, 苗健龙, 韩丽萍. TP53-EGFR共突变对非小细胞肺癌预后及治疗的研究进展[J]. 实用肿瘤学杂志, 2023, 37(3): 262-266.
[2]	王嘉倍, 张运广, 刘连新. 免疫治疗联合分子靶向药物治疗中晚期肝细胞癌的临床疗效及安全性分析:一项单臂回顾性研究[J]. 实用肿瘤学杂志, 2022, 36(6): 489-494.
[3]	吴蕊玥, 朱凯丽, 杨景茹, 令晓玲. HER2低表达乳腺癌的临床研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 570-575.
[4]	赵雅茹, 武云. 胃癌常见生物标记物及相应靶向治疗的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 483-488.
[5]	连晓敏, 马峰, 赵丽霞, 孟玮, 赵丹丹, 赵峻峰. PD-1抑制剂联合抗血管生成药物及化疗二线治疗晚期肺腺癌的临床对比分析[J]. 实用肿瘤学杂志, 2022, 36(4): 339-345.
[6]	郑艳丽, 贺建霞. 弥漫大B细胞淋巴瘤的DNA甲基化改变及治疗进展[J]. 实用肿瘤学杂志, 2022, 36(3): 259-262.
[7]	陈素, 隋红. 抗HER2治疗在转移性结直肠癌中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 288-292.
[8]	吴芳芳, 郑桐森. 胆道恶性肿瘤辅助治疗的研究现状及展望[J]. 实用肿瘤学杂志, 2022, 36(2): 156-161.
[9]	侯建勋, 王洪斌. 外泌体对乳腺癌诊疗一体化影响的研究进展[J]. 实用肿瘤学杂志, 2022, 36(2): 178-182.
[10]	马补换, 刘彩霞. Jagged1促进乳腺癌发生发展及远处转移的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 452-457.
[11]	杨思琦,宋启斌,李清清(综述),姚颐(审校). 靶向抑制FGFRs信号在治疗恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 73-77.
[12]	党瑶,皇甫辉,秦艺骁,车琴,郝晓龙(综述),王斌全(审校). 头颈部鳞状细胞癌转移机制及其影响因素研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 78-82.
[13]	宋家羽, 冯越, 王棹, 张云艳. 外泌体与妇科恶性肿瘤相关性的最新研究进展[J]. 实用肿瘤学杂志, 2020, 34(6): 571-575.
[14]	范晓娜, 王丹, 黎清炜, 李志伟. 胰腺癌术后辅助药物治疗的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 249-253.
[15]	刘超, 郑桐森. 新冠肺炎时期肿瘤内科工作的总结和反思[J]. 实用肿瘤学杂志, 2020, 34(2): 100-102.

抗EGFR治疗在头颈部鳞癌中的研究进展

Research progress of anti-EGFR therapy in head and neck squamous cell carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价